Not a good buy right now for an impatient trader: there is no Intellectia buy signal, the longer-term trend is still bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading like a high-risk micro-cap biotech without revenue.
Pre-market strength (0.745, +2.97%) is near resistance (R2 ~0.752), which limits immediate upside unless it breaks and holds above that level.
Net: avoid initiating a new position today; only consider if it cleanly breaks above ~0.752 with follow-through (otherwise the setup is not compelling).
Technical Analysis
Trend/MAs: Bearish structure (SMA_200 > SMA_20 > SMA_5) suggests the bigger-picture trend remains down despite the current bounce.
Momentum: MACD histogram is positive and expanding (0.00342), indicating short-term upside momentum is building.
RSI (6): 62.15 (neutral-to-slightly-warm), not yet overbought, but also not a deeply discounted “buy the dip” reading.
Levels: Pivot 0.724; Support S1 0.707 (then S2 0.696). Resistance R1 0.741 (already slightly exceeded pre-mkt) and R2 0.752 (next key ceiling). Pre-mkt price 0.745 is in the resistance zone.
Pattern-based odds: Similar-pattern stats imply modest expected move (next day ~-0.54%, next week ~+0.25%, next month ~+3.09%), which does not signal a strong edge for immediate buying.
Positive Catalysts
in pre-market.
Neutral/Negative Catalysts
makes price action prone to sharp reversals without catalysts.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: Dropped to 0 (down -100% YoY) — indicates no operating revenue base in the period.
Net income: Improved to -14.566M (up 79.52% YoY) — losses narrowed materially.
EPS: Improved to -0.36 (up 71.43% YoY) — per-share loss narrowed.
Gross margin: 0 (down -100% YoY), consistent with no revenue; overall improvement is from cost/expense dynamics rather than sales growth.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: On 2025-11-17, H.C. Wainwright raised the price target to $4 from $3 and maintained a Buy rating after the Q3 report.
Wall Street-style pros view: Improved loss trajectory (narrowing losses) supports the bull case; maintained Buy suggests the analyst believes pipeline/value inflection is possible.
Cons view: The fundamental “top-line” is effectively absent (revenue at 0), so the bull thesis is largely catalyst/pipeline-dependent; without fresh news flow, price targets can be slow to translate into near-term performance.
Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4 USD with a low forecast of 4 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BRNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRNS is 4 USD with a low forecast of 4 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.743
Low
4
Averages
4
High
4
Current: 0.743
Low
4
Averages
4
High
4
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$3 -> $4
AI Analysis
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $4
AI Analysis
2025-11-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Barinthus Biotherapeutics to $4 from $3 and keeps a Buy rating on the shares following the Q3 report.
